Skip to main content
Luoxin Pharmaceuticals Group Stock Co., Ltd. logo

Luoxin Pharmaceuticals Group Stock Co., Ltd. — Investor Relations & Filings

Ticker · 002793 ISIN · CNE1000026S7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,601 across all filing types
Latest filing 2026-01-13 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002793

About Luoxin Pharmaceuticals Group Stock Co., Ltd.

https://www.luoxin.cn

Luoxin Pharmaceuticals Group Stock Co., Ltd. focuses on the research, development, manufacturing, and distribution of diverse medicinal products. The company specializes in therapeutic areas including digestive health, respiratory medicine, anti-infectives, and oncology. Its portfolio includes various formulations such as injections, tablets, and capsules, with a notable emphasis on proton pump inhibitors and respiratory treatments. Luoxin operates a vertically integrated model, producing both active pharmaceutical ingredients (APIs) and finished dosage forms. The organization emphasizes innovation through dedicated R&D facilities to develop high-quality healthcare solutions. Its operations are supported by a comprehensive supply chain and manufacturing infrastructure designed to adhere to international quality standards, serving broad market segments with a focus on clinical efficacy and patient accessibility.

Recent filings

Filing Released Lang Actions
舆情管理制度
Governance Information Classification · 95% confidence The document is titled '舆情管理制度' which translates to 'Public Opinion Management System' or 'Media/Public Sentiment Management Policy' of the company. It outlines internal policies, organizational structure, responsibilities, and procedures for managing public opinion and media crises. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no capital changes, no legal proceedings, no executive changes, no earnings announcements, no investor presentations, or any other typical financial or regulatory report content. The document is a governance-related internal policy document approved by the board. It does not fit into financial reports or announcements but relates to governance practices and internal rules. Therefore, the best fitting category is Governance Information (CGR). The document length is 2919 characters, which is relatively short but contains substantive policy content, not just an announcement or certification. Hence, it is not RPA or RNS.
2026-01-13 Chinese
市值管理制度
Governance Information Classification · 95% confidence The document is titled '市值管理制度' (Market Value Management System) and outlines the company's policies and procedures for managing its market value, including principles, organizational responsibilities, capital operations, equity management, brand promotion, investor relations, and personnel requirements. It is a detailed internal governance document related to how the company manages its market value and investor relations, rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it an announcement of a report. It fits best as a Governance Information (CGR) filing, which covers internal rules, board structure, and governance practices.
2026-01-13 Chinese
独立董事候选人声明与承诺（郭云沛）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate for a company's board. It contains detailed attestations about the candidate's qualifications, independence, and compliance with relevant laws and regulations. There are no financial statements, earnings data, or report summaries. The document is not an announcement of a report publication but a formal statement related to board/management information, specifically about a director candidate's qualifications and commitments. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 4337 characters, which is consistent with a detailed declaration rather than a full report or announcement.
2026-01-13 Chinese
关于为控股子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Luoxin Pharmaceutical Group Co., Ltd. regarding the progress of guarantees provided to its controlling subsidiary. It details the guarantee amounts, contractual terms, financial data of the subsidiary, and board opinions on the guarantee risks. The document is an announcement about financing guarantees and risk disclosures rather than a financial report, audit, or earnings release. It does not contain comprehensive financial statements or detailed financial analysis but focuses on the update of guarantee activities and related risk disclosures. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company financing activities and guarantees.
2026-01-08 Chinese
关于转让控股子公司股权暨被动形成财务资助的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a transaction involving the transfer of equity in a controlling subsidiary and the resulting passive financial assistance. It details the board meeting approval, transaction overview, payment status, and subsequent steps. The document is relatively short (1010 characters) and focuses on a specific corporate action rather than providing comprehensive financial data or full report content. It does not contain financial statements or detailed financial analysis. Therefore, it is best classified as a Capital/Financing Update (CAP) since it relates to changes in capital structure and financing activities through equity transfer and related financial support.
2026-01-07 Chinese
关于为控股子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Luoxin Pharmaceutical Group Co., Ltd. regarding the progress of providing guarantees for its controlling subsidiary. It details the guarantee amounts, the contractual terms, financial data of the subsidiary, and board opinions on the guarantee. The document is an announcement about a financing-related guarantee activity rather than a full financial report or audit. It does not contain comprehensive financial statements or quarterly results but focuses on the update of guarantee provision progress and related contractual information. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2656 characters, which is consistent with an announcement rather than a full report. Hence, the classification is CAP with high confidence.
2026-01-06 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.